Clinical trial · Observational
Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer
NCT01831609CI-TRIAL-00059131unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To prospectively collect ascites, pleural fluid, circulating tumor cells and derived primary cultures from metastatic cancer patients. The specimens will be analyzed using DNA/RNA/proteomic approaches.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Biomarker analyses to predict treatment response in metastatic cancer
- timeFrame
- 3 year
- description
- Using patient derived tumor cells, predictive biomarker analyses (DNA, RNA protein levels etc) will be assessed.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients with histologically confirmed gastrointestinal, genitourinary, sarcoma, rare cancer 2. Written informed consent 3. body fluid derived from cancer, available for drainage and collection Exclusion Criteria: * patients who do not give informed consent form for research use of biomaterials/biospecimens
References
Publications (0)
Data not yet available
No reference posted for this study.